Immuno-Oncology Products

Tumor mutational burden (TMB) is one of the most promising biomarkers for the clinical understanding of patient response to immune check point inhibitors. Current clinical application of TMB has focused on the use of whole exome sequencing (WES), however, targeted NGS assays appear to be a much better fit for meeting needs of timely turn-around of patient test results and broader applicability beyond a few send-out clinical laboratories. Find out more about these products at : https://www.seracare.com/Controls---Reference-Materials-NGS-Somatic-Cancer-Tumor-Mutational-Burden/. Accurate and consistent TMB measurement by targeted NGS panels requires ground-truth controls with a range of TMB scores that support analytical validation of these assays to measure TMBs and the concomitant bio-informatics analysis pipelines for generating the patient TMB scores. SeraCare has partnered with key industry stakeholders to design, develop, and commercialize a range of human cell line-derived TMB reference standards that can be used to validate targeted NGS panels designed for TMB measurements and the concomitant TMB scoring informatics pipeline, allowing precise TMB measurements. We have developed new TMB reference standards from matched tumor-normal human cell lines in both purified gDNA and FFPE formats. These cell lines are primarily derived from diseased patients and their matched peripheral blood lymphoblastoid normal cell lines. High molecular weight DNAs were extracted and annotated for their TMB scores by whole exome sequencing. Find out more about these products at https://www.seracare.com/Controls---Reference-Materials-NGS-Somatic-Cancer-Tumor-Mutational-Burden/.